Rockwell Medical Reports Growth Amid Strategic Shifts

Introduction

Rockwell Medical, Inc. (Nasdaq: RMTI; Korean name: 록웰 메디컬) is a public healthcare company headquartered in Wixom, Michigan. Founded in 1996, it develops, manufactures, and distributes hemodialysis products—including liquid and dry acid and bicarbonate concentrates, and iron supplementation therapies—to dialysis providers worldwide.

Corporate Structure and Workforce

Rockwell Medical operates four U.S. facilities: its headquarters in Wixom, Michigan; manufacturing and distribution sites in Greer, South Carolina; Grapevine, Texas; and Washington, Iowa. The company employs between 201 and 500 people across research and development, manufacturing, quality assurance, and customer service functions.

Dialysis Products by Kristine Wook

Recent Developments and News

• March 20, 2025: Reported full-year 2024 net sales of $101.5 million (up 21 percent year-over-year) and gross profit of $17.5 million (up 101 percent). Adjusted EBITDA showed a positive figure for the first time. Q4 2024 net sales were $24.7 million (up 12 percent).
• April 1–4, 2025: Exhibited at DialysisTechConneXion42 in Las Vegas, featuring its CitraPure® and Dri-Sate® dry acid powders and DAMX45 mix system.
• Partnership with Innovative Renal Care: Under a three-year agreement (with a one-year extension option), Rockwell will supply IRC with liquid and dry acid and bicarbonate concentrates through 2028, ensuring continuity for U.S. dialysis centers.
• May 12, 2025: Announced Q1 2025 net sales of $18.9 million (down 17 percent from Q1 2024’s $22.7 million) and gross profit of $3.0 million (consistent year-over-year), accompanied by a conference call and webcast.
• 2025 Great Place to Work: Certified for the third consecutive year, based on employee feedback regarding workplace attributes.
• February 19, 2025: The company announced the passing of Terry Wright, Director of Transportation.

Financial and Strategic Analysis

Rockwell Medical’s 2024 performance showed growth in net sales and gross profit, leading to its first positive adjusted EBITDA. The 17 percent decline in Q1 2025 net sales contrasted with year-end performance, attributed primarily to order timing and concentrate delivery schedules. The company has shifted its focus away from U.S. New Drug Applications (NDAs) for its iron therapy Triferic, which was discontinued in Q4 2022, toward its core concentrates business and international markets. Partnerships in South Korea (Jeil Pharmaceutical) and Turkey (Drogsan; priority marketing submissions in April 2023 with approval anticipated in 2024) aim to expand non-U.S. revenue. An amended Schedule 13G/A filed May 15, 2025, reveals that Armistice Capital, LLC and Steven Boyd jointly hold 3,284,144 shares (4.99 percent of common stock).

Market Position and Industry Context

Rockwell Medical operates in a market where hemodialysis is the primary treatment for end-stage kidney disease. Its hemodialysis concentrates portfolio serves freestanding and hospital-based dialysis centers, skilled nursing facilities, and home dialysis patients. The company's emphasis on manufacturing reliability, regulatory compliance, and customer service supports its operations amid established competitors and changing reimbursement landscapes. Long-term supply agreements and participation in industry trade shows strengthen customer relationships and enhance visibility within the market.

tl;dr

On July 9, 2025, Rockwell Medical shares traded at $1.1652 (+25.13 percent) on Nasdaq (volume: 432,367). Full-year 2024 net sales were $101.5 million with positive adjusted EBITDA. Q1 2025 net sales of $18.9 million fell 17 percent year-over-year; gross profit remained at $3.0 million. A three-year supply agreement with Innovative Renal Care runs through 2028. International partnerships target markets in South Korea and Turkey. Future growth will depend on concentrate sales execution and non-U.S. expansion.